F. Millot Et Al. , "Switch to Subsequent Line of Treatment in Children and Adolescents with Chronic Myeloid Leukemia (CML) Treated with Imatinib: Experience of the International Registry for Chronic Myeloid Leukemia in Children and Adolescents (I-CML-Ped Study)," 57th Annual Meeting of the American-Society-of-Hematology , vol.126, Florida, United States Of America, 2015
Millot, F. Et Al. 2015. Switch to Subsequent Line of Treatment in Children and Adolescents with Chronic Myeloid Leukemia (CML) Treated with Imatinib: Experience of the International Registry for Chronic Myeloid Leukemia in Children and Adolescents (I-CML-Ped Study). 57th Annual Meeting of the American-Society-of-Hematology , (Florida, United States Of America).
Millot, F., Guilhot, J., Suttorp, M., Meunier, A. S., Meral, G. A., Sedlacek, P., ... de Bont, E.(2015). Switch to Subsequent Line of Treatment in Children and Adolescents with Chronic Myeloid Leukemia (CML) Treated with Imatinib: Experience of the International Registry for Chronic Myeloid Leukemia in Children and Adolescents (I-CML-Ped Study) . 57th Annual Meeting of the American-Society-of-Hematology, Florida, United States Of America
Millot, Frederic Et Al. "Switch to Subsequent Line of Treatment in Children and Adolescents with Chronic Myeloid Leukemia (CML) Treated with Imatinib: Experience of the International Registry for Chronic Myeloid Leukemia in Children and Adolescents (I-CML-Ped Study)," 57th Annual Meeting of the American-Society-of-Hematology, Florida, United States Of America, 2015
Millot, Frederic Et Al. "Switch to Subsequent Line of Treatment in Children and Adolescents with Chronic Myeloid Leukemia (CML) Treated with Imatinib: Experience of the International Registry for Chronic Myeloid Leukemia in Children and Adolescents (I-CML-Ped Study)." 57th Annual Meeting of the American-Society-of-Hematology , Florida, United States Of America, 2015
Millot, F. Et Al. (2015) . "Switch to Subsequent Line of Treatment in Children and Adolescents with Chronic Myeloid Leukemia (CML) Treated with Imatinib: Experience of the International Registry for Chronic Myeloid Leukemia in Children and Adolescents (I-CML-Ped Study)." 57th Annual Meeting of the American-Society-of-Hematology , Florida, United States Of America.
@conferencepaper{conferencepaper, author={Frederic Millot Et Al. }, title={Switch to Subsequent Line of Treatment in Children and Adolescents with Chronic Myeloid Leukemia (CML) Treated with Imatinib: Experience of the International Registry for Chronic Myeloid Leukemia in Children and Adolescents (I-CML-Ped Study)}, congress name={57th Annual Meeting of the American-Society-of-Hematology}, city={Florida}, country={United States Of America}, year={2015}}